10:34 AM EDT, 10/13/2025 (MT Newswires) -- 4D Molecular Therapeutics ( FDMT ) said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.

The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.

The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.

The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end

4D Molecular shares were down 1.9% in recent trading.

Price: 8.76, Change: -0.14, Percent Change: -1.57